|Year : 2018 | Volume
| Issue : 3 | Page : 239-241
Fluorodeoxyglucose-positive splenic infarctions are completely regressive just after 4 months
Sebastian Hoberueck1, Danilo Seppelt2, Ivan Platzek2, Klaus Zöphel1
1 Department of Nuclear Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany
2 Department of Radiology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany
|Date of Web Publication||11-Jun-2018|
Department of Nuclear Medicine, Universitätsklinikum der TU Dresden, Fetscherstr. 74, 01307 Dresden
Source of Support: None, Conflict of Interest: None
| Abstract|| |
A 55-year-old woman with newly diagnosed hepatocellular carcinoma (HCC) was hospitalized in our department for the evaluation of selective internal radiotherapy (SIRT), which consists of an angiography, an intra-arterial technetium (Tc)-99m-macroaggregated albumin application and Tc-99m sulfur colloid scintigraphy to assess liver function. Besides the modest intratumoral tracer accumulation, F-18-fluorodeoxyglucose (FDG) positron emission tomography–computed tomography (PET/CT) imaging showed two intense focal cuneiform splenic FDG accumulations which turned out to be splenic infarctions. Four months later, both hypermetabolic foci were completely regressive in the first follow-up PET/CT after SIRT. This is the first report of a complete metabolic regression of splenic infarctions within just 4 months, whereas regression on CT is commonly seen after more than 2 years.
Keywords: Fluorodeoxyglucose, hepatocellular carcinoma, metabolic regression, positron emission tomography, selective internal radiotherapy, splenic infarction, splenic metastasis
|How to cite this article:|
Hoberueck S, Seppelt D, Platzek I, Zöphel K. Fluorodeoxyglucose-positive splenic infarctions are completely regressive just after 4 months. Indian J Nucl Med 2018;33:239-41
|How to cite this URL:|
Hoberueck S, Seppelt D, Platzek I, Zöphel K. Fluorodeoxyglucose-positive splenic infarctions are completely regressive just after 4 months. Indian J Nucl Med [serial online] 2018 [cited 2022 Jan 26];33:239-41. Available from: https://www.ijnm.in/text.asp?2018/33/3/239/234132
| Introduction|| |
Even though uncommon, intensive focal splenic fluorodeoxyglucose (FDG) accumulations are mainly described to be of a malignant nature. Benign focal splenic accumulations of F-18-FDG are rarely reported. Ahmadzadehfar et al. reported a splenic lesion with a circular area of high FDG uptake with a central photopenic area that was suspected to be a necrotizing metastasis of malignant melanoma. Subsequent splenectomy revealed an infected splenic infarction. In another case, a splenic sclerosing hemangioma caused a false-positive finding in FDG PET., An infection with Leishmania has been reported to have shown intense focal FDG uptake.
| Case Report|| |
We present the case of a 55-year-old female patient with newly diagnosed hepatocellular carcinoma (HCC) who was hospitalized in our department for selective internal radiotherapy (SIRT). This was initially planned as a two-step procedure, with the right lobe to be treated first, due to its larger disease involvement.
The patient underwent a preinterventional evaluation, which consists of an angiography, an intra-arterial Tc-99m-macroaggregated albumin (MAA) application and scintigraphy  and a Tc-99m-sulfur colloid scintigraphy to assess liver function.
After the evaluation, the patient underwent a FDG-positron emission tomography–computed tomography (PET/CT) scan for staging, in which HCC showed a typical modest FDG accumulation and no extrahepatic tumor manifestations. Surprisingly, two intense focal cuneiform FDG accumulations were detected in the spleen [Figure 1].
|Figure 1: Maximum intensity projection of the patient's initial fluorodeoxyglucose-positron emission tomography–computed tomography. Two intense, focal, cuneiform splenic lesions (blue arrows). The hepatocellular carcinoma shows typical modest fluorodeoxyglucose uptake|
Click here to view
On CT images, these two lesions showed the typical configuration of acute infarctions with wedge-shaped subcapsular contrast defects, especially in the venous phase. These lesions were not seen in the preliminary examination 1 month ago, in which HCC was initially observed.
Retrospectively, notable findings were seen in the pre-SIRT evaluations performed on the day before PET/CT. In the Tc-99m-sulfur colloid scintigraphy, there were cuneiform photopenic areas in the spleen [Figure 2]. In the conventional angiography, the infarct area showed slightly lower contrast. In the Tc-99m-MAA scintigraphy, there was no tracer accumulation in the spleen.
|Figure 2: 99mTc-sulfur colloid scintigraphy: cuneiform lineal photopenic areas in the infarct regions (blue arrows). In addition, multiple hepatic photopenic lesions due to hepatocellular carcinoma are visible|
Click here to view
In the first follow-up PET/CT 4 months after SIRT, the formerly focal hypermetabolic infarcted areas showed no increased FDG uptake anymore. However, they were still detectable on CT although smaller.
Several follow-up examinations were performed over the next 28 months without any new infarctions or other pathologic lesions in the spleen. The last follow-up CT showed a complete morphologic regression of both infarcted areas as well.
| Discussion|| |
Acute splenic infarctions are a rare differential diagnosis to the well-known metastatic etiology of most focal FDG accumulations. They can be caused by bacterial infections, coagulopathies, and hematological/oncological or cardiovascular diseases and are usually restricted to subcapsular areas of the splenic parenchyma. Furthermore, an association of splenic infarctions and therapy with sorafenib for HCC has been described by a single case report, whereas in the present case, no pretreatment was applied. Apart from of a slightly elevated C-reactive protein (7.4 mg/L), probably caused by the HCC itself, neither the PET/CT nor clinical or other imaging examinations revealed any sign of an infection. Coagulation parameters such as the international normalized ratio and activated partial thromboplastin time were in the normal range, and the patient had no history of cardiac disease or arrhythmia.
Splenic infarctions related to radioembolization are reported as a rare side effect. Due to the lack of other risk factors as mentioned above, we assume that the infarctions were caused by the diagnostic angiography performed during the SIRT evaluation.
As the patient was asymptomatic, no therapeutic consequences resulted from the splenic infarctions. No anticoagulation was necessary, and SIRT could have been performed as scheduled 2 weeks (right liver lobe) and 6 weeks (left liver lobe) after evaluation.
Splenic infarctions can present as a focal tracer accumulation in FDG PET and are a noteworthy differential diagnosis to malignant splenic FDG accumulations.
It is worth pointing out that there has been a rapid metabolic regression at the level of unaffected splenic parenchyma, much faster than seen on CT. Within 4 months, the infarcted areas could not be metabolically distinguished from unaffected splenic tissue [Figure 3] in the PET images.
|Figure 3: Long-term development of the splenic infarction: from top to bottom: fused fluorodeoxyglucose-positron emission tomography–computed tomography, venous phase of the contrast-enhanced computed tomography, and fluorodeoxyglucose-positron emission tomography. From the left to right: initial examination with typical hypermetabolic, acute splenic infarction, follow-up after 4 months with complete metabolic regression, an incomplete morphologic regression, and follow-up after 28 months with both metabolic and morphologic regression of the acute splenic infarction|
Click here to view
To the best of our knowledge, this is the first published case of complete metabolic regression of a splenic infarction, after only 4 months.
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Ahmadzadehfar H, Brockmann H, Schmiedel A, Biersack HJ, Ezziddin S. Splenic infarction mimicking a necrotizing metastasis of malignant melanoma on F-18 FDG PET/CT. Clin Nucl Med 2008;33:571-2.
Al-Ibraheem A, Buck AK, Dechow T, Ringshausen I, Langer R, Engels HP, et al.
Splenic sclerosing haemangioma causes false-positive finding at FDG-PET. Nuklearmedizin 2010;49:N20-1.
Dong A, Wang Y, Lu J, Zuo C. Enhanced CT and FDG PET/CT findings of splenic hamartoma. Clin Nucl Med 2014;39:968-71.
Fuertes J, Garcia-Bennett JR, Iftimie S, Danús M, Abreu JA. Focal splenic FDG uptake in a patient with kala-azar (visceral leishmaniasis). Clin Nucl Med 2014;39:387-90.
Uliel L, Royal HD, Darcy MD, Zuckerman DA, Sharma A, Saad NE, et al.
From the angio suite to the γ-camera: Vascular mapping and 99mTc-MAA hepatic perfusion imaging before liver radioembolization – a comprehensive pictorial review. J Nucl Med 2012;53:1736-47.
Matesan MM, Bowen SR, Chapman TR, Miyaoka RS, Velez JW, Wanner MF, et al.
Assessment of functional liver reserve: Old and new in 99mTc-sulfur colloid scintigraphy. Nucl Med Commun 2017;38:577-86.
Henker R, Keim V, Karlas T. Acute infarction of the spleen. Dtsch Arztebl Int 2017;114:382.
Kim SO, Han SY, Baek YH, Lee SW, Han JS, Kim BG, et al.
Splenic infarction associated with sorafenib use in a hepatocellular carcinoma patient. World J Gastroenterol 2011;17:267-70.
Michl M, Haug AR, Jakobs TF, Paprottka P, Hoffmann RT, Bartenstein P, et al.
Radioembolization with yttrium-90 microspheres (SIRT) in pancreatic cancer patients with liver metastases: Efficacy, safety and prognostic factors. Oncology 2014;86:24-32.
[Figure 1], [Figure 2], [Figure 3]